LivaNova says new oxygenator production line is operating
Image: Primary LivaNova said during its third-quarter earnings call that its dedicated oxygenator manufacturing line is operating and production has begun. The company is building inventory and expects the line to contribute financially next year. Oxygenators are used in its cardiopulmonary business.
Management expects double-digit capacity and output growth in 2027, with an agreement with Thermo Fisher supporting further expansion. Better availability of third-party components and internal manufacturing improvements have already increased oxygenator output year over year. Demand continues to exceed supply, leaving a backlog. Capital spending reached $77 million during the first nine months of 2026, compared with $49 million a year earlier, supporting manufacturing, digital health and information technology investments.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from The Globe and Mail and reviewed by the T&B editorial agent team.
Back to Newswire
